Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 96

Results For "PLI"

3329 News Found

Lonza outlines strategy, new organizational structure and guidance
News | December 12, 2024

Lonza outlines strategy, new organizational structure and guidance

The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities


Brenntag Specialties engages Esprit Care for its Southeast Asia nutraceutical market expansion
Supply Chain | December 12, 2024

Brenntag Specialties engages Esprit Care for its Southeast Asia nutraceutical market expansion

Brenntag Specialties Pharma marks a strategic milestone with its first collaboration with a contract manufacturer to enhance its nutraceutical value chain


Lupin receives tentative approval from USFDA for Abacavir, Dolutegravir and Lamivudine tablets for oral suspension
Drug Approval | December 09, 2024

Lupin receives tentative approval from USFDA for Abacavir, Dolutegravir and Lamivudine tablets for oral suspension

The fixed-dose combination of Abacavir 60 mg/Dolutegravir 5 mg/Lamivudine 30 mg tablets for oral suspension is a once-daily single-pill regimen


Suven to acquire 56% stake in ADC specialist NJ Bio for US$64.4 million
News | December 09, 2024

Suven to acquire 56% stake in ADC specialist NJ Bio for US$64.4 million

This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape


Supriya Lifescience expands global footprint with Esketamine Hydrochloride approval
News | December 09, 2024

Supriya Lifescience expands global footprint with Esketamine Hydrochloride approval

Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market


NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis
News | December 07, 2024

NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis

Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator


Muna Therapeutics and GSK to accelerate development of novel treatments for Alzheimer’s disease
Biotech | December 07, 2024

Muna Therapeutics and GSK to accelerate development of novel treatments for Alzheimer’s disease

GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization


FDA RMAT status for Affimed and Artiva’s lymphoma combo therapy
Drug Approval | December 07, 2024

FDA RMAT status for Affimed and Artiva’s lymphoma combo therapy

Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients


AstraZeneca appoints Iskra Reic as Executive Vice President, International
People | December 06, 2024

AstraZeneca appoints Iskra Reic as Executive Vice President, International

Iskra has held leadership positions across Central & Eastern Europe, Eurasia, Middle East & Africa at AstraZeneca